Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Calls for Post-Launch Premiums for Add’l Indications, Evidence
June 17, 2019
- Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
- JPMA Nudges PMDA to Increase Int’l Staffers, Drive Harmonization in Asia
June 12, 2019
- Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
- Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
- Generic Industry Calls for Support for API Purchase Cost, Revision of Gx Pricing: LDP Study Group
June 3, 2019
- JPMA Asks Govt to Buy 1.3 Billion Yen Cryo-EM Equipment to Fuel Drug Discovery
May 29, 2019
- JPWA Pushing for September Announcement of New NHI Prices
May 27, 2019
- Medipal Pres. Watanabe Elected as New JPWA Chief
May 24, 2019
- Professor Calls for More Balanced Healthcare Resource Allocation, Higher Copay for Minor Illnesses
May 24, 2019
- Hodanren Renews Call for Transparent Pricing for Kymriah
May 23, 2019
- OTC Industry Group to Up Its Efforts to Reduce “Switch Lag”
May 22, 2019
- Sales of Japan CRO Association Members Down 1.2% to 190 Billion Yen in 2018; Pharma Sales Up 2.6%
May 22, 2019
- Wholesaler Group to Set Up Own Rules for Information Provision by Autumn
May 21, 2019
- Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA
May 16, 2019
- Payer Reps Stress Need to Revise Coverage of Drugs for Minor Illnesses; Kymriah’s Price Isn’t Necessarily too High
May 16, 2019
- Number of Contract Sales Reps Down 11.5% in FY2018: JCSOA
April 19, 2019
- GHIT Fund to Leverage Japanese Technology to Benefit Neglected Patients around the World: New CEO
April 18, 2019
- Regenerative Medicine Groups in Asia Begin Discussions towards Mutual Approval
April 15, 2019
- JPMA Not Envisioning Asia-Version EMA at This Point: Chief
April 11, 2019
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…